Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Imaging And Path LabBOM:544482 -2.22%21 EBITDA Margin % is 38.10% as of Mar. 2026, which is 29% above its 10-year median of 29.45. GuruFocus rates BOM:544482 with a GF Score™ of 21/100. Among 203 Medical Diagnostics & Research companies, Star Imaging And Path Lab ranks better than 97.04% on this metric.
Star Imaging And Path Lab (BOM:544482) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Star Imaging And Path Lab EBITDA Margin % Related Terms
Star Imaging And Path Lab EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:544482 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Star Imaging And Path Lab's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Imaging And Path Lab EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Star Imaging And Path Lab's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Star Imaging And Path Lab's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Imaging And Path Lab (BOM:544482) has a EBITDA Margin % of 38.10% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Star Imaging And Path Lab and its competitors. This is 29% above median its historical median of 29.45. Over the past decade, Star Imaging And Path Lab's EBITDA Margin % has ranged from 10.17 to 38.59. According to the industry distribution chart, Star Imaging And Path Lab ranks #6 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 3%.
Is Star Imaging And Path Lab's EBITDA Margin % too high?
Star Imaging And Path Lab's current EBITDA Margin % of 38.10% is 29% above median its 10-year median of 29.45. Over the past 10 years, this metric has ranged from a low of 10.17 to a high of 38.59. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Star Imaging And Path Lab's value of 38.10% is 662% above this industry median. Based on the distribution chart, Star Imaging And Path Lab ranks #6 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Star Imaging And Path Lab has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Star Imaging And Path Lab's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Star Imaging And Path Lab ranks #6 out of 203 companies for EBITDA Margin %. This places Star Imaging And Path Lab in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 5.00. Star Imaging And Path Lab's value of 38.10% is 662% above this benchmark. Historically, Star Imaging And Path Lab's own EBITDA Margin % has ranged from 10.17 to 38.59 over the past decade. While the company's 10-year median is 29.45 vs. the industry median of 5.00, Star Imaging And Path Lab has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Imaging And Path Lab's current EBITDA Margin % of 38.10% is 662% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Star Imaging And Path Lab and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Imaging And Path Lab's current EBITDA Margin % is 38.10%, which is 29% above median its own 10-year median of 29.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Imaging And Path Lab stock overvalued right now?
Star Imaging And Path Lab (BOM:544482) has a current EBITDA Margin % of 38.10%. The current EBITDA Margin % is 38.10%, which is 29% above median its 10-year median of 29.45 and 662% above the Medical Diagnostics & Research industry median of 5.00. Star Imaging And Path Lab's overall GF Score™ is 21/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Star Imaging And Path Lab (BOM:544482), the current EBITDA Margin % is 38.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Star Imaging And Path Lab Ltd operates a diagnostic testing network, NABL accredited, delivering pathology, radiology, Cardiology, and Neurology services in Delhi and Uttar Pradesh. It offers a comprehensive range of diagnostic imaging services and clinical laboratory tests, including both routine and specialized studies and profiles. These services are essential for the prediction, early detection, diagnostic screening, confirmation, and monitoring of diseases. The company's diagnostic imaging and radiology services encompass X-rays, computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, ultrasounds, bone mineral densitometry, and mammography.
21GF Score
Get the complete analysis for BOM:544482
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544482 has been successfully added to your 
